Gabapentin Tablet, Film Coated
Product Images NDC 72162-2141

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 72162-2141). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Ab1e0185 B802 4cf2 A5d4 B71f27f1dcb0 00)

An equation illustrating estimated creatinine clearance (CLCr) calculation, showing the formula incorporating age, weight, serum creatinine, and a correction factor for female patients.*

FDA Label Image

Chem Structure (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 01)

Chemical structure of gabapentin showing a cyclohexane ring bonded to an aminomethyl and carboxymethyl group.*

FDA Label Image

Figure01 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 02)

A line graph showing mean pain scores over an 8-week period comparing placebo and gabapentin 3600 mg/day. The x-axis represents weeks, starting from baseline through week 8, while the y-axis shows mean pain scores from 0 to 10. The graph indicates a 4-week dose titration period followed by a 4-week fixed dose period.*

FDA Label Image

Figure02 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 03)

A line graph showing mean pain scores over 7 weeks. It compares placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day. The timeline includes a 3-week dose titration period followed by a 4-week fixed dose period, with pain scores decreasing more for Gabapentin groups than placebo.*

FDA Label Image

Figure03 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 04)

A bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing response rates in two studies. It shows response percentages for placebo (PBO) and Gabapentin (GBP) at various doses, with GBP doses 3600 mg, 1800 mg, and 2400 mg showing higher responder rates than placebo.*

FDA Label Image

Figure4 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 05)

A scatter plot chart showing the percentage difference on the y-axis and daily dose in milligrams on the x-axis. The graph compares data points from three studies labeled 'a', 'b', and 'c' at different gabapentin daily doses (600 mg, 900 mg, 1200 mg, 1800 mg), illustrating the relationship between daily dose and effect differences.*

FDA Label Image

Label (Lbl721622141)

Gabapentin Tablets, USP 600 mg film-coated tablets, oral use, labeled by Bryant Ranch Prepack and manufactured by ACI Healthcare Limited. The label indicates 100 tablets per container with storage instructions at 20° to 25°C (68° to 77°F). The NDC is 72162-2141-1 and the product is for prescription use only.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.